期刊文献+

心肺运动试验对评估肺动脉高压患者西地那非药物效果的作用 被引量:7

Evaluation of Cardiopulmonary Exercise Testing on Sildenafil Effect for Treating the Patients With Pulmonary Arterial Hypertension
下载PDF
导出
摘要 目的:探讨心肺运动试验对评估肺动脉高压患者西地那非药物效果的作用。方法:入选2012-01至2014-01阜外医院新诊断的仅接受西地那非治疗的动脉性肺动脉高压患者25例,于基线,治疗后6~12个月、13~18个月评估患者心肺运动试验、心脏超声、心功能、6 min步行距离和N末端B型脑钠肽原(NT-pro BNP)的变化。结果:与正常对照组相比,动脉性肺动脉高压患者用氧能力(峰值氧耗量,峰值氧脉搏)以及通气效率(呼气末二氧化碳分压,分钟通气量与二氧化碳排出量比值)明显下降(P均〈0.05)。西地那非治疗(8±2)个月后,用氧能力以及通气效率明显改善,同时心功能、6 min步行距离和NT-pro BNP也出现改善(P均〈0.05)。继续西地那非治疗(16±2)个月时,6 min步行距离变化不明显(P=0.26),但峰值氧耗量、峰值氧脉搏较(8±2)个月时下降(P=0.04,0.06),通气效率减低(表现为呼气末二氧化碳分压下降、分钟通气量与二氧化碳排出量比值升高,P=0.04和0.04)以及NT-pro BNP开始出现增加(P=0.05)。结论 :心肺运动试验能有效评估肺动脉高压患者西地那非治疗疗效并指导用药。 Objective: To evaluate cardiopulmonary exercise testing (CPET) on sildenaifl effect for treating the patients with pulmonary arterial hypertension (PAH). Methods: A total of 25 PAH patients received sildenaifl treatment in our hospital from 2012-01 to 2014-01 were enrolled as PAH group, in addition, there were a Control group including 24 healthy subjects. The CPET, echocardiography, NYHA function class, 6-mimute walking distance (6MWD) and plasma levels of NT-proBNP at the baseline, (6-12) months and (13-18) months after sildenaifl treatment were assessed and compared between 2 groups. Results: Compared with Control group, PAH group showed decreased aerobic capacity (peakVO?2, Peak O2pulse) and ventilation efifciency (PETCO2@AT, VE/VCO2@AT), allP〈0.05. At (8±2) months after sildenaifl treatment, aerobic capacity and ventilation efifciency was improved, meanwhile, NYHA function class, 6MWD and plasma levels of NT-proBNP were improved, allP〈0.05. At (16±2) months after sildenaifl treatment, 6MWD was similar,P=0.26, while peak VO?2 and peak O2 pulse were decreased than they were at (8±2) months after sildenaifl treatment,P=0.04 and 0.06; the ventilation efifciency was elevated (as presented by increased VE/VCO2@AT and decreased PETCO2@AT,P=0.04 and P=0.04); plasma level of NT-proBNP was increased,P=0.05. Conclusion: CPET can effectively evaluate sildenaifl effect for treating PAH patients and therefore and guide the drugs therapy.
作者 唐毅 柳志红 安辰鸿 马秀平 熊长明 倪新海 罗勤 赵智慧 赵青 张洪亮 王勇 黄智伟 金旗 TANG Yi LIU Zhi-hong AN Chen-hong MA Xiu-ping XIONG Chang-ming NI Xin-hai LUO Qin ZHAO Zhi-hui ZHAO Qing ZHANG Hong-liang WANG Yong HUANG Zhi-wei JIN Qi(Department of Cardiology, Cardiovascular Institute and Fu Wai Hospital, CMAS and PUMC, Beijing (100037), China)
出处 《中国循环杂志》 CSCD 北大核心 2016年第9期881-884,共4页 Chinese Circulation Journal
基金 中央级公益性科研院所(编号:2015-F06)项目名称:应用心肺运动试验评估不同类型肺动脉高压患者靶向药物效果
关键词 高血压 肺性 西地那非 心肺运动试验 Hyperteusion,pulmonary Sildenaifl Cardiopulmonary exercise testing
  • 相关文献

参考文献20

  • 1de Jesus Perez VA. Molecular pathogenesis and current pathology of pulmonary hypertension. Heart Fail Rev, 2015, 21: 239-257.
  • 2Wang RC, Jiang FM, Zheng QL, et al. Efficacy and safety of sildenafil treatment in pulmonary arterial hypertension: a systematic review. Respir Med, 2014, 108: 531-537.
  • 3Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. New Engl J Med, 2005, 353: 2148- 2157.
  • 4Gabler NB, French B, Strom BL, et al. Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation, 2012, 126: 349-356.
  • 5Savarese G, Paolillo S, Costanzo P, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol, 2012, 60:1192-1201.
  • 6赵青,柳志红,马秀平,赵智慧,罗勤,顾晴,熊长明,张洪亮,王勇.心肺运动试验比较三种肺动脉高压患者心肺功能状态的价值[J].中华医学杂志,2015,95(44):3598-3601. 被引量:3
  • 7赵智慧,柳志红,顾晴,罗勤,赵青,熊长明,倪新海.心肺运动试验在慢性血栓栓塞性肺动脉高压评估中的应用[J].中华医学杂志,2013,93(22):1687-1690. 被引量:6
  • 8刘伟华,柳志红,罗勤,赵青,奚群英,马秀平,赵智慧.继发于肺动脉高压的慢性右心衰竭与继发于左心疾病的慢性全心衰竭患者通气功能的差异[J].中国循环杂志,2014,29(12):996-999. 被引量:4
  • 9Wensel R, Opitz CF, Anker SD, et al. Assessment of survival in patients with primary pulmonary hypertension: Importance of cardiopulmonary exercise testing. Circulation, 2002, 106:319-324.
  • 10Hoeper MM, Faulenbach C, Golpon H, et al. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respiratory J, 2004, 24: 1007-1010.

二级参考文献19

  • 1Sun XG, Hansen JE, Oudiz R J, et al. Exereise pathophysiolagy in patients with primary pulmonary hypertension. Cir:ulation, 2001, 104: 429- 435.
  • 2Barst RJ, I,angleben D, Frost A, el a[. Sitaxsentan therapy tkr puhnonary arterial hypertension. Am J l/espir Crit Care Med, 2004, 169 : 441-447.
  • 3Wense| R, Opitz CF, Anker SD, el al. Assessment of smwival in patients in patients with primal-y pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulatim, 2002. 106: 319-324.
  • 4Gali/e N, Itoeper MM, Humbert M, et al. Guidelines fir |he diagnosis and tieatment of pulmonary hypertension : the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) , endorsed by the lnteraationa] Society of Hear/and Lung Transplantation ([SHLT). Eur Heart J, 2009, 30 : 2493- 2537.
  • 5Jaff MR, McMurWy MS, Aher SI, el al. Management of massive and sabmassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboemboli( puhnonary hypertension: a scientific statement ii'om the American Heari Association. Circulation, 2011 , 123 : 1788-1830.
  • 6Zhai Z, Murphy K, Tighe H, et al. Differences in ventilatory inefficiency between pulmonary arterial hypertension and chronic thromboembolie puhnonary hypertension. Chest, 2011 , 140: 1284-1291.
  • 7HumbertM, KhaltaevN, BousquetJ, et al. Pulmonary hypertension: from an orphan disease to a public health problem[J]. Chest, 2007, 132(2): 365–367.
  • 8WenselR, FrancisDP, MeyerFJ, et al. Incremental prognostic value of cardiopulmonary exercise testing and resting haemodynamics in pulmonary arterial hypertension[J]. Int J Cardiol, 2013, 167(4): 1193–1198.
  • 9CaianiEG, CorsiC, SugengL, et al. Improved quantification of left ventricular mass based on endocardial and epicardialsurface detection with real time three dimensional echocardiography[J]. Heart, 2006, 92(2):213–219.
  • 10McLaughlinVV, ArcherSL, BadeschDB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association[J]. J Am Coll Cardiol, 2009, 53(17): 1573–1619.

共引文献10

同被引文献58

引证文献7

二级引证文献59

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部